Stockreport

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio, Inc.  (IBIO) 
NASDAQ:AMEX Investor Relations: ir.ibioinc.com
PDF SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary d [Read more]